- FDA approval based on MARCH Phase 3 study with highly statistically significant (p
Mirum Pharmaceuticals’ LIVMARLI Receives FDA Approval for Treatment of Cholestatic Pruritus in Patients with Progressive Familial Intrahepatic Cholestasis
On 6ix: 6ix.com/news/mirum-pharmaceuticals-livmarli-receives-fda-approval-for-treatment-of-cholestatic
Watch Mirum Pharmaceuticals' latest callMirum Pharmaceuticals (NASDAQ:MIRM) Q2 2026 Earnings Call · Replay · Aug 5Read the transcript of Mirum Pharmaceuticals (NASDAQ:MIRM) Q2 2026 Earnings CallMirum Pharmaceuticals, Inc. on 6ix
Story so far
- Hepatology Publishes Six-Year Data Demonstrating Improved Clinical Outcomes in Patients with Alagille Syndrome Treated with Mirum’s LIVMARLI
- Mirum Pharmaceuticals Announces New PDUFA Date for LIVMARLI for the Treatment of Cholestatic Pruritus in Progressive Familial Intrahepatic Cholestasis
- Mirum Pharmaceuticals Announces Positive Phase 3 RESTORE Study Results Evaluating Chenodal in Patients with Cerebrotendinous Xanthomatosis
Earlier from Mirum Pharmaceuticals
- Hepatology Publishes Six-Year Data Demonstrating Improved Clinical Outcomes in Patients with Alagille Syndrome Treated with Mirum’s LIVMARLI
- Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Business Update
- Mirum Pharmaceuticals to Announce Fourth Quarter and Year-End 2023 Financial Results and Host Conference Call on February 28, 2024
- Mirum Pharmaceuticals Appoints Joanne Quan, MD as Chief Medical Officer
- Mirum Pharmaceuticals Announces Preliminary Unaudited 2023 Net Revenue and Provides Corporate Updates
Later from Mirum Pharmaceuticals
- Mirum Pharmaceuticals’ LIVMARLI (maralixibat oral solution) Receives Positive Reimbursement Recommendation by Canada’s CADTH for Patients with Cholestatic Pruritus in Alagille Syndrome
- Mirum Pharmaceuticals to Announce First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024
- Mirum Announces Publication of Phase 3 MARCH Data in The Lancet Demonstrating Benefits of LIVMARLI (maralixibat) in patients with PFIC
- Mirum Pharmaceuticals to Present at the Citizens JMP Life Sciences Conference
- Mirum Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
Follow Mirum Pharmaceuticals into a list and get an email when it puts out news.
Follow Mirum Pharmaceuticals